In recent months, everyone’s been raving about the potential in the Illinois cannabis market, but the truth is they’re overlooking an even greater opportunity.
Newsweek, for example, says, “Illinois [is set] to record $1 billion in cannabis sales by year’s end.”
And NBC Chicago says, “Illinois cannabis sales continue to smash records, with revenue exceeding that of liquor.”
But despite all the fanfare, another state has already surpassed Illinois in terms of cannabis revenue.
And at this point, the media still hasn’t caught on yet.
Michigan has slowly risen the ranks since full legalization was passed, and it is now on track to make up an enormous $3 billion market.
That puts it only behind California and Colorado, both of which had a massive head start after being among the first states to legalize recreational cannabis use.
But with close to 250,000 medical patients residing in Michigan, the state currently has the same number of medical card holders as all of Canada.
All that to say that demand is soaring in the Great Lakes State. And after full adult-use was legalized, demand has only continued to rise since dispensaries opened in December 2019.
In fact, cannabis revenue skyrocketed by 585% in Michigan during its first year after legalization.
And keep in mind, this was all during a year where customers were largely not allowed in retail dispensaries due to the pandemic.
Today, Gage Growth Corp. (CSE: GAGE | OTC:GAEGF) is moving towards becoming the #1 market share leader in the fast-growing state.
And the numbers are showing they’re only continuing to build on that goal.
After raising $50 million in December/January, Gage made an impressive announcement on their recent revenues.
They reported that for Full Year 2020, revenue increased 1,972% to a whopping $39.9 million.
That comes out to a 20X increase in revenue in just one year. Even better, most recently, the company reported its Q1-2021 results, posting record revenue of $17.6 million, an increase of 219.4% year-over-year and 67.9% quarter-over-quarter. The company ended the first quarter of 2021 with over $43.6 million of cash.
You’d be hard-pressed to find that kind of growth anywhere else in the markets.
Learn how Gage Growth Corp. is moving towards becoming the market share leader in America’s fastest-growing cannabis state – Read our exclusive report!
But early numbers are already proving to be even more impressive for this year.
For example, Gage just reiterated its guidance for Q2-2021 revenue of $26-31 million.
That incredible growth potential is a major reason why Jason Wild has been one of their biggest shareholders.
Wild is the executive chairman of leading cannabis company, TerrAscend, and he has an incredible track record for spotting gems in the industry.
For instance, he was an early backer of Canopy Growth Corp. That’s long before it became the $10 billion behemoth it is today.
And with Gage’s premium product yielding a premium price, he clearly sees the potential of this fast-growing cannabis company.These premium prices have helped amount to an average basket size of $164 in 2020.
Compare that to Michigan’s average basket size of $85, and you’ll see why the numbers look so promising for this company.
That has helped them land agreements with 5 or more contract growers to cultivate more of their product around the state.
These agreements allow Gage to save valuable capital on the front end while immediately increasing their supply on the shelves.
But they don’t rely on these partners exclusively, as they’ve developed their own massive footprint of cultivation and production facilities. When combining both owned cultivation footprint and contract grows, the company’s cultivation capacity is expected to increase to 3,000 lbs by July and 7,000 by year end.
Continuing Their Massive Growth Trend
Gage Growth Corporation covers every step of the process as a vertically integrated cannabis company.
That means they control everything from the cultivation of the flower to cutting and drying the product to packaging it on their shelves.
This kind of hands-on touch allows them to ensure they provide the highest quality, premium product possible.
They do it all in their cultivation and production facilities using a high-quality, low-cost, indoor production method.
Combined with contract grow, their total footprint of over 250,000 square feet allows them to produce up to 3,000 pounds of cannabis flower per month by July.
That’s expected to increase to 7,000 pounds per month by year end.
Discover why early investors are so confident Gage Growth Corp. could soar after establishing more Michigan retail locations – Click here to download our special report now!
And they use that to produce a broad portfolio of high quality products.
But they’ve also taken it a step further by partnering with one of the most well-known brands in the cannabis space.
Cookies is one of the most prolific and respected cannabis lifestyle brands in the markets.
That’s why this California-based premium cannabis brand has been able to develop partnerships with major hip-hop artists like Snoop Dogg, Wiz Khalifa, and Rick Ross.
And now, Gage Growth Corp. has signed an exclusive partnership with Cookies in Michigan.
This partnership has earned them instant credibility and added more reach on social media, giving them the ability to easily grow their brand and product to a larger audience.
And they’re using this same strategy to amplify their brand with other key partners like Blue River, Lemonnade, Grandiflora Genetics, Runtz, and more.
While Gage’s numbers have proven they’ve had a successful year in 2020 by any measure, their ambitious plans could make this year even more impressive.
- After opening their 9th retail location, they expect to have 20+ stores open and operating by the end of 2021.
- They’re planning to have a processing lab opened in the third quarter.
- And they also have several other Michigan-based acquisition opportunities in progress.
When you compare Gage to competitors, it instantly becomes clear how grossly undervalued the company is at the moment too.
Take, for example, their revenues for the biggest holiday in cannabis culture: 4/20.
Gage drove over $505,000 in revenue that day.
That’s roughly on par with what industry peer, Planet 13 Holdings, brought in as well.
But currently, Planet 13 boasts a massive market cap of $1 billion.
Which means Gage, with a market cap of approximately $500 million, is driving numbers at the level of major players more than 4 times their size.
Now, as Gage Growth Corp. is set to continue their aggressive growth in one of the top cannabis revenue-producing states in the nation…
The time is right for early investors to follow one of the best hidden opportunities in the growing Michigan cannabis market.
IMPORTANT NOTICE AND DISCLAIMER
This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Gage Growth Corp. to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of five hundred thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.
CHANGES IN SHARE TRADING AND PRICE
Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.
NO OFFER TO SELL OR BUY SECURITIES
This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.
Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.
This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.
NO FINANCIAL ADVICE
The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.
FORWARD LOOKING STATEMENTS
This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.
INDEMNIFICATION/RELEASE OF LIABILITY
By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.
All trademarks used in this communication are the property of their respective trademark holders. Other than valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than valuethemarkets.com.
valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.
ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of valuethemarkets.com, has been paid for the production of this piece by the company or companies mentioned above.otc pandemic canada
Naturally Splendid says select Denny’s Canada Restaurants to Offer NATERA meat alternative entrees
VANCOUVER – Naturally Splendid Enterprises Ltd. (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) reported that select Denny’s restaurants in Canada will be carrying three NATERA meat-alternative entrees on their menus. Denny’s will be offering NATERA…
VANCOUVER – Naturally Splendid Enterprises Ltd. (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) reported that select Denny’s restaurants in Canada will be carrying three NATERA meat-alternative entrees on their menus.
Denny’s will be offering NATERA Garlic Chick-Un Kiev, Seasoned Chick-Un Tenders and Chick-Un Nuggets at five of their BC restaurant locations mid-late June: Denny’s on Broadway, Denny’s Richmond, Denny’s Kingsway, Denny’s at Mt Lehman, and Denny’s Langley. The carefully chosen selection of NATERA products will be prepared and served using Denny’s signature seasonings and sauces, making them unique for their much-valued customers.
Offering NATERA meat-alternatives is an extension of Denny’s commitment to serving quality food without sacrificing flavour or value and extends their commitment to sourcing products that satisfy customer needs.
Naturally Splendid CEO Mr. J. Craig Goodwin states, “Denny’s is an iconic brand in Canada having been in operation for over 60 years and we are proud to provide NATERA entrees to this well-known family dinner. In addition to better personal health, choosing to eat more plant-based foods will drastically cut your carbon footprint as well as reduce water consumption making the planet healthier as well. Whether you’re vegetarian or flexitarian or just looking to try plant-based entrees, you can experience the great taste of NATERA foods in the comfortable setting of a Denny’s Restaurant.”
“Denny’s is a place founded in community, where everyone can enjoy great tasting food at a great value, and we are proud to offer menu items that benefit the health of our guests and communities. In partnership with the team at Naturally Splendid, we are excited to launch the test of seven NATERA-inspired entrees to guests at five of our restaurants in B.C. Upon successful completion of the test, and when all dining restrictions are lifted, we look forward to introducing our most popular NATERA menu items at most Denny’s locations across Canada.” said Deborah Gagnon, President & COO, Denny’s Canada
According to a survey conducted by Dalhousie University and the University of Guelph as part of a study examining awareness of Canada’s Food Guide, 6.5 million Canadians – nearly 20 per cent of the population (up from 6.4 million in October 2018) – are either limiting the amount of meat they eat (the so-called flexitarian diet) or cutting it out entirely.
Although COVID may have accelerated the popularity of plant-based food, there are multiple factors driving the growth of plant-based eating. These include concern for the environment, health and wellness, ethics, and diversity in protein sourcing. The shift towards plant-based diets is being driven by consumer concern surrounding health and wellbeing as well as sustainable farming and Naturally Splendid is pleased to be working with Denny’s to support this most worthy lifestyle initiative.
Founded in 2010, NSE operates a Safe Quality Food Level 2 certified food manufacturing facility just outside Vancouver, BC in Canada. The Company has established numerous healthy, functional foods under recognized brands such as Natera Sport, Natera Hemp Foods, CHII, Elevate Me and Woods Wild Bar, and most recently Natera Plant Based Foods, a line of delicious plant-based meat alternatives for the rapidly growing plant-based market segment. The Company has a myriad of new products and line extensions under development that are approaching launch. NSE, through its joint venture Plasm Pharmaceutical, has been approved for conducting a phase 2 clinical trial approved by Health Canada for treatment of COVID-19. NSE has also developed proprietary technologies for the extraction of high-demand, healthy omega 3 and 6 oils from hemp. NSE contract manufacturers for healthy, functional food products and ingredients focusing on plant-based ingredients. The Company provides contract manufacturing services for many healthy food companies, private labeling a wide variety of nutritional food products destined for global healthy food markets.
Vancouver-based Dencan Restaurants Inc. currently owns and operates 59 Denny’s Restaurants across Canada and is owned by Northland Properties Corporation. Part of the highly-regarded worldwide Denny’s organization, Dencan Restaurants Inc. has a well-deserved reputation, quality, and guest satisfaction. From fluffy pancakes to crispy bacon and juicy burgers to something from the Fit Fare® Menu, guests will always find delicious value and variety.
We seek Safe Harbor.otc covid-19 treatment canada bc
Best Biotech Penny Stocks to Buy? 3 to Watch Before Monday
Looking for biotech penny stocks to watch before Monday? Check these 3 out
The post Best Biotech Penny Stocks to Buy? 3 to Watch Before Monday appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Biotech Stocks Continue to Grow Amid Falling Covid Cases
Over the past year and a half, biotech stocks, and biotech penny stocks, in particular, have become a major talking point. Because of Covid, more investors are focusing on the biotech industry than in many years prior.
And, this makes sense given that there are plenty of penny stocks working on Covid-related treatments. However, in the past six months, investors have broadened their focus beyond those companies just working on a Covid vaccine or compound.
Now, we are seeing an overall interest in the biotech industry as a whole. This is true whether it be groundbreaking new medicines or better versions of medical devices. So, because momentum is high, plenty of penny stocks to watch in the biotech industry have reached record highs in the past few months.
While trading volume over that time was relatively low and the market has been trading mostly sideways, investors are excited about the future. As Covid cases decline to the lowest rate in months, and more than 2 billion vaccine doses have been administered globally, the next few months could be fruitful.
But, traders are also cautious, and this fear is illustrated through the trading we’ve witnessed since around April. Moving forward, investors should pay attention to the news and what is occurring worldwide. This is the best way to try and stay ahead of the game. Considering this, let’s take a look at three biotech penny stocks for your morning watchlist.
3 Biotech Penny Stocks to Watch Right Now
Tyme Technologies Inc. (NASDAQ: TYME)
Tyme Technologies Inc. is a biotech penny stock that has been performing well in the market recently. The company develops cancer metabolism therapies in the United States. One of its lead candidates is SM-88 which is in several Phase II/III clinical trials to treat 15 different types of cancer.
This includes but is not limited to lung, breast, prostate, lymphoma, sarcoma, and other types of cancer. It also has TYME-18 which is a CMBT compound in preclinical stages to treat solid tumors. Given that this compound has the potential to treat so many different types of cancer, it could take some time before approval is granted. However, the broadness of its scope is a major benefit for Tyme and investors alike.
Tyme has not released any recent company-specific updates in the past few weeks. However, it does plan on hosting a conference call on June 10th after the market closes. This is when the company will report conclusions from its comprehensive strategic review and outline its updated business plan. Tyme will also report its fiscal year financial results on the same date. These are both sizable events to take note of. Conference calls and balance sheets give a unique insight into what a company is doing now, and what it could do in the coming months.
On the trading day before this took place, TYME stock pushed up substantially. And, in the past month, shares of TYME have shot up by over 30%. With this being said, it is important to stay up to date with any advancements made by the company. In biotech, things always move fast, so updates are extremely important. With this in mind, will TYME make your list of penny stocks to watch?
Axcella Health Inc. (NASDAQ: AXLA)
Axcella Health Inc. is another biotech penny stock that is growing substantially in many recent trading sessions. Over the past five days, AXLA stock has shot up 55%. Despite being down around 14% in early market trading, many investors are showing bullish sentiment for Axcella.
For some context, the company treats complex diseases and enhances health with endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, to treat overt hepatic encephalopathy, AXA1125 to treat non-alcoholic steatohepatitis, and more.
While no company-specific news drove yesterday’s substantial gain, we can dig a little deeper to try and explain this. Recently, Senda Biosciences, another biotech company, announced that it closed a $98 million Series B financing deal. One participant in this deal was Flagship Pioneering, which is a company that develops first-in-category life science platform companies that are transforming human health and sustainability. And, a company under its umbrella is, you guessed it, Axcella Health. While this does not purely relate to AXLA, often we see correlative momentum when one event occurs in the biotech industry.
On the day of this announcement, shares of AXLA stock rose more than 48% in the market. AXLA stock opened at $3.44 per share and closed at $5.13 per share, making it no longer a penny stock. At one point, AXLA reached as high as $5.89 per share, which is quite a substantial intraday move. With all of this information in mind, will you add AXLA stock to your list of penny stocks to watch?
iBio Inc. (NYSE: IBIO)
iBio Inc. is a biotech penny stock that provides contract development and manufacturing services. These services are offered to collaborators and third-party customers. Its therapeutic and lead candidate is IBIO-100. This compound holds an investigational new drug development designation to treat systemic scleroderma, idiopathic pulmonary fibrosis, and more. It has many other trials making advancements as well at the moment. So what is causing this recent 6% uptick in IBIO stock price?
Well, iBio is currently developing a COVID-19 vaccine candidate. It has not been approved for use yet, but often companies related to COVID developments will perform well in the meantime. The company provided a corporate update in mid-May that gave investors some insight as to where the company is now at.
“Our focus on strategy execution was reflected in our third-quarter results as we advanced our second-generation COVID-19 vaccine candidate, defended our intellectual property rights, and achieved strong year-over-year revenue growth while adding new development services clients.”The Chairman and CEO of iBio, Tom Isett
While treatments surrounding Covid can provide major room for speculation, it’s best to consider the other compounds in iBio’s pipeline. It’s worth noting that IBIO and the biotech industry right now, tend to be highly speculative. But, given that IBIO stock has a lot of momentum behind it right now, will it make your watchlist?
Which Biotech Penny Stocks Are You Watching?
Finding the best biotech penny stocks to buy can be challenging. But, with the internet at our fingertips, doing research has never been easier. Considering this, it’s best to consider the factors that go beyond pure speculation.
This means understanding what compounds a company has in its pipeline, and what its short and long-term goals are. With this in mind, there is plenty of momentum in the biotech industry right now. So, which biotech penny stocks are you watching?nasdaq stocks covid-19 penny stocks vaccine clinical trials preclinical small caps
Best Growth Penny Stocks for 2021, Are Small-Caps Worth Watching?
Top growth penny stocks to watch this year? Check these 3 out right now
The post Best Growth Penny Stocks for 2021, Are Small-Caps Worth Watching? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
3 Growth Penny Stocks to Watch Right Now
Finding growth penny stocks in 2021 can be challenging. With the rise of assets like Bitcoin, DogeCoin, small-caps and everything in between, this year has already become one for the books.
Yesterday on June 10th, we saw the small-name biotech penny stock Orphazyme ADR (NASDAQ: ORPH) shoot up by over 900% in a single day. It’s worth noting that shares have since fallen by more than 70%. This is a great example of the hyper-volatility we see often with penny stocks. And while the case for ORPH stock is one of its own, we do see large intraday moves often, albeit not usually as large as this.
So, when investing in penny stocks, it’s crucial to understand your risk tolerance and portfolio goals. This is the best way to ensure that any penny stocks you want to buy, align with your tolerance for price fluctuations. While many penny stocks are extremely volatile, there are quite a few that show solid levels of stability. It simply comes down to knowing where to look.
With penny stocks, it’s also extremely important to do as much research as possible. This way, you can stay ahead of the game and expect the unexpected. Considering all of this, here are three growth penny stocks to watch in 2021 and beyond.
3 Growth Penny Stocks For Your 2021 Watchlist
1. Xinyuan Real Estate Co. Ltd. (NYSE: XIN)
Up by a solid 20% or so at midday is Xinyuan Real Estate Co. Ltd. For some context, XIN is a real estate developer working primarily out of China. Additionally, it manages large scale, high quality real estate projects in over twelve cities across the country.
Recently, XIN moved into the New York real estate market, which has been known to be highly lucrative. Yesterday, it announced big news, which could be a potential reason behind todays gain. In early morning trading on June 10th, Xinyuan announced the completion of five newly constructed properties across China.
“We are thrilled to have completed five high-quality accommodations. These projects further exemplify our commitment to construction excellence and the Company’s dedication to meeting and exceeding client demands. Providing comfortable and convenient real estate related products and services to middle-class consumers will continue to be our top priority.”Mr. Zhang Yong, Chairman of Xinyuan Group
Right now, the real estate market around the world is booming. There are a few reasons why this is the case. For one, as we enter a post-Covid era many people are beginning to buy homes again.
In the U.S. for example, near-zero interest rates combined with massive stimulus given out over the past year, mean that people have more free income to rent and purchase homes. And in China, massive industrial projects like the ones completed yesterday for XIN, can begin again. Considering all of this, will XIN make your list of penny stocks to watch?
2. Biolase Inc. (NASDAQ: BIOL)
Biolase Inc. is a penny stock that we have covered frequently over the past few months. Up by around 4% at midday, Biolase is as its name suggests, a biotech penny stock. But, instead of manufacturing drugs, Biolase produces laser systems for use in doctors office, and primarily for dental applications.
Last week, the company announced that two studies reported in the International Journal of Periodontics & Restorative Dentistry and Lasers in Medical Science, support its new proprietary laser technology.
“Although studies can vary, data suggests as much as 56% of people with dental implants may have peri-implantitis. Unfortunately, treatment methods for peri-implantitis can be painful, costly, ineffective and unpredictable.
The findings of these recent studies confirm that Waterlase laser technology can be a more viable treatment option than alternative methods. We look forward to continuing to provide dentists with minimally invasive treatment options through advanced laser technology that benefits their patients.”John Beaver, CEO of Biolase
While dental procedures were understandably down during the pandemic, they have since increased back to pre-Covid levels. This could be one of the main reasons that shares of BIOL stock have jumped by a solid 170% over the past six months.
And, with more people going to see their dentists following a year of not being able to go into the office, Biolase could see higher adoption of its technologies. While its laser systems can be pricy, they do offer a fantastic alternative for common procedures. With this in mind, will BIOL stock make your watchlist this year?
3. Aptinyx Inc. (NASDAQ: APTX)
One of the biggest gainers of the day is Aptinyx Inc. By midday, shares of APTX stock were up by as much as 41% to just over $4.50 per share. Today’s momentum could be coming from a TIpRanks article titled ‘“Strong Buy” Penny Stocks That Could Rally to $10 or More”. While this is not any news related to the company, we see massive speculation across the board with penny stocks due to something as simple as an article put out.
But, besides the hype from one article, those who wish to invest in APTX should do their own research. To better understand APTX, we have to look at its financials. Last month, Aptinyx reported its Q1 2021 financial results as well as some highlights from the quarter. By the end of the period, Aptinyx reported holding around $146 million in cash on hand. It states that this should support its operations until at least 2023.
“We have made excellent progress across our clinical stage programs over the past few months. This progress was exemplified by our positive meeting with the FDA regarding our development of NYX-783 in PTSD, and the recommencement of our Phase 2 study of NYX-458 in patients with Parkinson’s disease and dementia with Lewy bodies.”Norbert Riedel, PhD., CEO of Aptinyx
These two trials alone are both interesting and important for investors to consider. Moreover, its large cash flow is something that we do not see as often with biotech companies. Considering this and the above events, will APTX be on your list of penny stocks to watch?
Is 2021 the Year That Penny Stocks Take Off?
Many investors are excited about the coming months for penny stocks. With Covid cases in a massive decline, traders seem hopeful that the near future could bring increased momentum for the entire stock market.
Although there are some fears of the new variants of the virus, early studies show that vaccines are still effective. This means that a return to normalcy could be entirely possible. Because Covid has such a large effect on the stock market right now, staying up to date with all related news is very important. With all of this in mind, is 2021 the year that penny stocks take off?nasdaq stocks pandemic bitcoin real estate penny stocks
Novavax says Covid-19 vaccine shows immune response against Beta virus variant
Venezuela Says US Sanctions Blocking COVID Vaccines: ‘Global Health System’ As Geopolitical Weapon
Cannabis Weekly Round-Up: NFL to Spend US$1 Million on Cannabis Research
How COVID-19 exposed the systemic ageism at the heart of Britain
TDR’s Top 5 Psychedelic Developments For The Week Of June 7
UK To Extend Lockdown One Month As Indian Variant Spooks Officials Into Vaccine Scramble
European stocks inch to new highs on ECB recovery outlook
Dollar lower following higher U.S. inflation data
It’s Inflation Jim, But Not as We Know it…
Does a plant-based diet really help beat COVID-19?
Spread & Containment18 hours ago
Novavax says Covid-19 vaccine shows immune response against Beta virus variant
Bonds11 hours ago
Weekend Recap: Inflation Soars But Who Cares?
Science19 hours ago
Market in Review: Last Week’s Darlings and Duds
Spread & Containment5 hours ago
Venezuela Says US Sanctions Blocking COVID Vaccines: ‘Global Health System’ As Geopolitical Weapon
Government20 hours ago
TDR’s Top 5 Psychedelic Developments For The Week Of June 7
Economics19 hours ago
The Hangover Arrives: Explosive Inflation Leads To Record Collapse In Home, Car Purchase Plans
Stocks12 hours ago
Is there a right way to regulate crypto? Yes, and this is how
Government18 hours ago
FDA Tells J&J to Discard Millions of COVID-19 Vaccine Doses Manufactured by Emergent BioSolutions